Diff Profiles › MTBLS4709_0001_00000001

Hanks_balanced_salt_solution_vs_doxycycline

Hank's balanced salt solution vs doxycycline

p-value ≤ 0.05 3 significant 2025-09-26 00:00:00 Study: MTBLS4709
18 Total Features
3 Significant
0.05 p-value Threshold

Profile details

Identifier
MTBLS4709_0001_00000001
Linked study
MTBLS4709 — Fatty acid oxidation protects cancer cells from apoptosis through increasing mitochondrial membrane lipids
Comparison
Hank's balanced salt solution vs doxycycline
Group A
Control group treated with Hank's balanced salt solution.. Provides baseline for comparison with doxycycline-treated samples.
Group B
Treatment group receiving doxycycline.. Represents the effect of doxycycline treatment on the samples.
Total features tested
18
Significant features
3
p-value threshold
0.05
Ratio threshold (upper)
1.5
Ratio threshold (lower)
1/1.5
Date created
2025-09-26 00:00:00

Top hits

Metabolite ID (InChI Key) Name Direction Ratio p-value
XSSUJRSOHXBICQ-GPDPEMMZSA-N [(2R)-2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate up 1.703 5.18e-05
LOVKBDFNFACEND-HSEDGGQWSA-N PC(14:0/22:1) up 1.801 0.000164
JQKOHRZNEOQNJE-DJEJVYNPSA-N 2-azaniumylethyl (2<i>R</i>)-2-[(9<i>Z</i>)-octadec-9-enoyloxy]-3-(stearoyloxy)propyl phosphate up 2.275 0.0398